226 related articles for article (PubMed ID: 7550353)
1. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
Cairns P; Polascik TJ; Eby Y; Tokino K; Califano J; Merlo A; Mao L; Herath J; Jenkins R; Westra W; Rutter JL; Buckler A; Gabrielson E; Tockman M; Cho KR; Hedrick L; Bova GS; Isaacs W; Koch W; Schwab D; Sidransky D
Nat Genet; 1995 Oct; 11(2):210-2. PubMed ID: 7550353
[TBL] [Abstract][Full Text] [Related]
2. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene.
Wiest JS; Franklin WA; Otstot JT; Forbey K; Varella-Garcia M; Rao K; Drabkin H; Gemmill R; Ahrent S; Sidransky D; Saccomanno G; Fountain JW; Anderson MW
Cancer Res; 1997 Jan; 57(1):1-6. PubMed ID: 8988029
[TBL] [Abstract][Full Text] [Related]
4. p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Williamson MP; Elder PA; Shaw ME; Devlin J; Knowles MA
Hum Mol Genet; 1995 Sep; 4(9):1569-77. PubMed ID: 8541841
[TBL] [Abstract][Full Text] [Related]
5. Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Schmid M; Malicki D; Nobori T; Rosenbach MD; Campbell K; Carson DA; Carrera CJ
Oncogene; 1998 Nov; 17(20):2669-75. PubMed ID: 9840931
[TBL] [Abstract][Full Text] [Related]
6. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
7. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas.
Cairns P; Tokino K; Eby Y; Sidransky D
Cancer Res; 1995 Jan; 55(2):224-7. PubMed ID: 7812948
[TBL] [Abstract][Full Text] [Related]
8. Homozygous deletions at 9p21 in childhood acute lymphoblastic leukemia detected by microsatellite analysis.
Takeuchi S; Koike M; Seriu T; Bartram CR; Slater J; Park S; Miyoshi I; Koeffler HP
Leukemia; 1997 Oct; 11(10):1636-40. PubMed ID: 9324282
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
10. Evidence for two candidate tumour suppressor loci on chromosome 9q in transitional cell carcinoma (TCC) of the bladder but no homozygous deletions in bladder tumour cell lines.
van Tilborg AA; Groenfeld LE; van der Kwast TH; Zwarthoff EC
Br J Cancer; 1999 May; 80(3-4):489-94. PubMed ID: 10408858
[TBL] [Abstract][Full Text] [Related]
11. Detection of CDKN2 deletions in tumor cell lines and primary glioma by interphase fluorescence in situ hybridization.
Dreyling MH; Bohlander SK; Adeyanju MO; Olopade OI
Cancer Res; 1995 Mar; 55(5):984-8. PubMed ID: 7867008
[TBL] [Abstract][Full Text] [Related]
12. Refined mapping of genomic rearrangements involving the short arm of chromosome 9 in acute lymphoblastic leukemias and other hematologic malignancies.
Dreyling MH; Bohlander SK; Le Beau MM; Olopade OI
Blood; 1995 Sep; 86(5):1931-8. PubMed ID: 7544647
[TBL] [Abstract][Full Text] [Related]
13. Homozygous deletions within chromosomal bands 9p21-22 in bladder cancer.
Stadler WM; Sherman J; Bohlander SK; Roulston D; Dreyling M; Rukstalis D; Olopade OI
Cancer Res; 1994 Apr; 54(8):2060-3. PubMed ID: 7513608
[TBL] [Abstract][Full Text] [Related]
14. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
15. Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.
Gonzalez-Zulueta M; Bender CM; Yang AS; Nguyen T; Beart RW; Van Tornout JM; Jones PA
Cancer Res; 1995 Oct; 55(20):4531-5. PubMed ID: 7553622
[TBL] [Abstract][Full Text] [Related]
16. Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer.
An HX; Niederacher D; Picard F; van Roeyen C; Bender HG; Beckmann MW
Genes Chromosomes Cancer; 1996 Sep; 17(1):14-20. PubMed ID: 8889502
[TBL] [Abstract][Full Text] [Related]
17. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction.
Cairns P; Tokino K; Eby Y; Sidransky D
Cancer Res; 1994 Mar; 54(6):1422-4. PubMed ID: 8137242
[TBL] [Abstract][Full Text] [Related]
19. Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B.
Herman JG; Jen J; Merlo A; Baylin SB
Cancer Res; 1996 Feb; 56(4):722-7. PubMed ID: 8631003
[TBL] [Abstract][Full Text] [Related]
20. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Stadler WM; Olopade OI
Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
